New Issue: Brace for a Correction!

Let’s seek lower volatility that’s safer than biotech, but still offers a 50%-plus gain. While the Nasdaq slips, our eye is on the Dow.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Jim Rickards’ Strategic Intelligence

LoginGet Access

Jim Rickards

James G. Rickards is the editor of Strategic Intelligence, Crash Speculator, Gold Speculator and Tactical Currency Profits. An Ex-CIA insider, he is also an American lawyer, economist, government advisor and investment banker with 40 years of experience working in capital markets on Wall Street. He was the principal negotiator of the...

View More By Jim Rickards